Staar surgical affirms that no acquisition proposals have been received from any party other than alcon

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa) (“staar”), the global leader in phakic iols with the evo family of implantable collamer® lenses (evo icl™) for vision correction, today issued the following statement: broadwood partners' statements and assertions regarding interest in staar are misleading and distort the truth. broadwood is misrepresenting introductory emails as offers to acquire staar. as previously disclosed, the communications from party a and b wer.
ALC Ratings Summary
ALC Quant Ranking